Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma
Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma
复制标题
骨桥蛋白和E-钙粘蛋白的异常表达表明宫颈癌患者的放射抵抗和不良预后
DOI：
10.1369/0022155414561329
复制
发表时间：
2015-02-01
影响因子：
3.2
通讯作者：
Chen, Xiang
中科院分区：
文献类型：
--
作者：
Huang, Xinqiong;Qian, Yujie;Chen, Xiang
放疗是宫颈癌各个阶段的一线治疗方法，无论是用于根治性治疗还是姑息性治疗。然而，宫颈癌的放射耐药仍然是一个主要的治疗问题。因此，我们探讨了e -钙粘蛋白（上皮-间质转化的标志物）和骨桥蛋白是否可以预测局部晚期宫颈鳞状细胞癌（LACSCC）患者的放射耐药。对患者进行回顾性分析，根据无进展生存期（PFS）将111例患者分为耐辐射组和辐射敏感组。在预处理的石蜡包埋组织中，我们使用免疫组织化学染色评估e -钙粘蛋白和骨桥蛋白的表达。放射耐药组骨桥蛋白高表达、e -钙粘蛋白低表达的患者比例显著高于放射敏感组（p<0.001）。这些患者的5年PFS率也较低（p<0.001）。我们的研究表明，高骨桥蛋白而低e -钙粘蛋白表达可被认为是LACSCC患者的一个阴性、独立的预后因素（[风险比（95% CI） 6.766 (2.940, 15.572)], p<0.001）。
Radiotherapy is the first-line treatment for all stages of cervical cancer, whether it is used for radical or palliative therapy. However, radioresistance of cervical cancer remains a major therapeutic problem. Consequently, we explored if E-cadherin (a marker of epithelial-mesenchymal transition) and osteopontin could predict radioresistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC). Patients were retrospectively reviewed and 111 patients divided into two groups (radiation-resistant and radiation-sensitive groups) according to progression-free survival (PFS). In pretreated paraffin-embedded tissues, we evaluated E-cadherin and osteopontin expression using immunohistochemical staining. The percentage of patients with high osteopontin but low E-cadherin expression in the radiation-resistant group was significantly higher than those in the radiation-sensitive group (p<0.001). These patients also had a lower 5-year PFS rate (p<0.001). Our research suggests that high osteopontin but low E-cadherin expression can be considered as a negative, independent prognostic factor in patients with LACSCC ([Hazard ratios (95% CI) 6.766 (2.940, 15.572)], p<0.001).